Table 1

Retrieved data from included studies on living guideline activities in low-income and middle-income countries

Study name (author, year)Publication date (dd/mm/yyyy)Document type (article, grey literature)Search date/frequencyLanguage usedStudy designType of study (quantitative, qualitative, mixed)Study settingClinical topics investigated
WHO, 20222414 July 2022ArticleNo informationEnglishCross-sectional (report)QuantitativeWHORecommendations against the use of fluvoxamine and colchicine) for non-severe COVID-19 patients.
WHO, 20222523 June 2022ArticleNo informationEnglishCross-sectional (report)QuantitativeWHODrug treatment for mild, moderate or severe COVID-19 patients.
Lamontagne F et al,26 20211 March 2021ArticleNo informationEnglishCross-sectional (report)QuantitativeWHORecommendations against use of hydroxychloroquine in patients without COVID-19.
WHO, 20222725 April 2022ArticleNo informationEnglishCross-sectional (report)QuantitativeWHORecommendations for infection prevention and control of COVID-19 in healthcare and community settings.
Arnav Agarwal. Et al,29 202231 March 2021ArticleNo informationEnglishCross-sectional (report)QuantitativeWHOA recommendation against the use of ivermectin for the treatment of COVID-19.
Arnav Agarwal. Et al,29 202225 April 2022ArticleNo informationEnglishCross-sectional (report)QuantitativeWHODosing of Ritonavir and Remdesivir for comorbid renal failure and COVID-19 patients.
Arnav Agarwal. Et al,29 20222 April 2022ArticleNo informationEnglishCross-sectional (report)QuantitativeWHOMolnupiravir use in patients with non-severe COVID-19.
WHO, 2021317 November 2021ArticleNo informationEnglishCross-sectional (report)QuantitativeWHOConvalescent plasma for COVID-19 treatment.
Arnav Agarwal. Et al,29 202224 September 2021ArticleNo informationEnglishCross-sectional (report)QuantitativeWHOUse of casirivimab and imdevimab combinations in non-severe COVID-19.
WHO, 2021317 November 2021ArticleNo informationEnglishCross-sectional (report)QuantitativeWHOCasirivimab–imdevimab combination therapy for COVID-19 patients.
Ibrahim K. et al,41 20225 July 2022ArticleNo informationEnglishCross-sectionalQuantitativeLebanonThe conception of a framework defining the processes involved in developing healthcare living practice guidelines.
Ge L, Zhu H et al,36 20213 August 2021ArticleNo information/twice monthyEnglishCross-sectionalQuantitativeChinaDrug treatment recommendations for mild to moderate COVID-19 patients in China.
Lamontagne F et al,26 20215 January 2021Commentary10/08/2020/no informationEnglishCross-sectional (report)QuantitativeWHOCorticosteroid treatments vs standard supportive treatments for COVID-19 patients.
François Lamontagne et al,26 20204 September 2020ArticleNo informationEnglishCross-sectional (report)QuantitativeWHORecommendations on corticosteroid therapy versus standard supportive care for COVID-19.
Liang N et al,37 20221 February 2022ArticleNo informationChineseCross-sectionalQuantitativeChinaThe development of rapid and living Chinese medicine guidelines for decision-making during public health emergencies.
Ignacio Neumann et al,40 202230 March 2022ArticleNo informationEnglishCross-sectionalQuantitativeChileThe application of explicit thresholds for determining evidence certainty in the COVID-19 treatment guideline.
Rochwerg B et al,34 20211 October 2021Review articleNo informationEnglishCross-sectional (report)QuantitativeWHOA review of living guidelines developed to address the use of COVID-19 treatment drugs.
Schwartz et al,35 202024 November 2020Review articleNo informationEnglishCross-sectional (report)QuantitativeWHOA recommendation against the use of remdesivir therapy for COVID-19.
Vogel et al,14 201929 June 2019ArticleMarch to October 2016/no informationEnglishCross-sectional (report)QuantitativeWHOA dynamic living guidelines approach to maternal and prenatal health management.
Zhang Qian et al,38 2021April 2021ArticleNo informationChineseCross-sectionalQuantitativeChinaA general overview of the development of China’s living guidelines.
Wang Q et al,39 2021October 2021ArticleNo informationChineseCross-sectionalQuantitativeChinaProposal of a living evidence-based guideline for the combination of traditional Chinese and Western medicine in treatment of COVID-19.